Kernick, David
Kondori, Nazanin
Pain, Andrew
Mount, Julie
Appel, Camilla
Ranopa, Michael
Gulati, Tania
Article History
Received: 1 March 2023
Accepted: 12 December 2023
First Online: 24 January 2024
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. No experimental protocols were used in this study. Data from the CPRD were obtained under licence from the UK Medicines and Healthcare Products Regulatory Agency. The use of CPRD data for this study was approved through the CPRD’s Research Data Governance Process (eRAP protocol 2021_000567, approved 24 November 2021). As CPRD data are anonymized, informed consent was not required for use in the study.
: Not applicable.
: Nazanin Kondori, Andrew Pain, Julie Mount, Camilla Appel, Michael Ranopa and Tania Gulati are employees of Eli Lilly and Company. David Kernick declares advisory and education work for Allergan, Eli Lilly and Company, Novartis, Pfizer and Teva.